Autoimmune clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

    open to eligible people ages 18 years and up

    The goal of this clinical study is to learn more about the study drug Anitocabtagene autoleucel (anito-cel), and its safety, tolerability, dosing, and preliminary effectiveness in participants with generalized myasthenia gravis (GMG). Anito-cel is a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy. The primary objective of this study is to assess the safety profile, including any dose-limiting toxicity (DLT) and identification of a maximum tolerated dose (MTD) (if applicable), to support selection of the recommended Phase 2 dose (RP2D) of anito-cel when administered to participants with GMG.

    Los Angeles, California and other locations

Last updated: